Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis

PHASE1TerminatedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

October 17, 2019

Primary Completion Date

September 2, 2021

Study Completion Date

September 2, 2021

Conditions
Primary Sclerosing CholangitisCompensated Cirrhosis
Interventions
DRUG

Cilofexor

Tablets administered orally once daily

Trial Locations (16)

11030

Northwell Health Center for Liver Diseases and Transplantation, Manhasset

14642

University of Rochester Medical Center, Rochester

22908

University of Virginia Medical Center, Charlottesville

23226

Bon Secours Richmond Community Hospital, Inc. d/b/a Bon Secours Liver Institute of Richmond, Richmond

23298

VCU Clinical Research Services Unit (CRSU) [Patient Site Address], Richmond

30309

Piedmont Atlanta Hospital, Atlanta

33136

Schiff Center for Liver Diseases/University of Miami, Miami

46202

Indiana University Health University Hospital, Indianapolis

55117

Minnesota Gastroenterology, PA, Maplewood

71105

Louisiana Research Center, LLC, Shreveport

75203

The Liver Institute at Methodist Dallas Medical Center, Dallas

85224

Arizona Liver Health, Chandler

91105

California Liver Research Institute, Pasadena

94143

University of California San Francisco, Liver Clinic, San Francisco

98104

University of Washington at Harborview Medical Center, Seattle

98105

Liver Institute Northwest, Seattle

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gilead Sciences

INDUSTRY